N-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenyl)-5-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide | 1052114-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenyl)-5-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide
• 英文别名: N-(3-fluoro-4-{1H-pyrrolo[2,3-b]pyridin-4-yloxy}phenyl)-5-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide；5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(2-hydroxyethyl)-4-oxopyridine-3-carboxamide
• CAS: 1052114-90-5
• 化学式: C₂₇H₂₀F₂N₄O₄
• 分子量: 502.477
• InChiKey: QBTATHILVDSJQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)aniline 、 5-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以105 mg的产率得到N-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenyl)-5-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide
  参考文献：
  名称：

  Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities

  摘要：

  Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC(50) value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors Such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent anti proliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC(50) values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTI-16 human gastric carcinoma xenograft model.

  DOI：

  10.1021/jm800476q

文献信息

• Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities
  作者：Kyoung Soon Kim、Liping Zhang、Robert Schmidt、Zhen-Wei Cai、Donna Wei、David K. Williams、Louis J. Lombardo、George L. Trainor、Dianlin Xie、Yaquan Zhang、Yongmi An、John S. Sack、John S. Tokarski、Celia Darienzo、Amrita Kamath、Punit Marathe、Yueping Zhang、Jonathan Lippy、Robert Jeyaseelan、Barri Wautlet、Benjamin Henley、Johnni Gullo-Brown、Veeraswamy Manne、John T. Hunt、Joseph Fargnoli、Robert M. Borzilleri

  DOI：10.1021/jm800476q

  日期：2008.9.11

  Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC(50) value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors Such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent anti proliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC(50) values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTI-16 human gastric carcinoma xenograft model.